Fig. 2: PAK6 increases the chemoresistance to oxaliplatin in GC cells.

a, b The expression of PAK6 in HGC-27, SGC-7901, BGC-823, AGS, and MGC-803 GC cell lines. c–f Knock down of the expression of PAK6 in 823 (c, d) and AGS (e, f) GC cells. g–j Overexpressing the expression of PAK6 in 7901 (g, h) and 803 (i, j) GC cells. k–n Dose-response curves of control cells or PAK6 knocked down cells in 823 (k) and AGS (l) GC cells after treated with oxaliplatin for 24 h. The IC₅₀ of the oxaliplatin in the 823 cell line are 18.701(823-Ctrl cells), 11.710 (823-PAK6-KD1 cells), and 10.960 (823-AK6-KD2 cells) μg/ml. The IC₅₀ of the oxaliplatin in the AGS cell line are 6.233 (AGS-Ctrl cells), 2.904 (AGS-PAK6-KD1 cells), and 1.969 (AGS-PAK6-KD2 cells) μg/ml. Dose-response curves of control cells or PAK6 overexpression cells in 7901 (m) and 803 (n) GC cells after treated with oxaliplatin for 24 h. The IC₅₀ of the oxaliplatin in the cells are 10.890 (7901-Ctrl cells), 21.250 (7901-PAK6 cells), 1.236 (803-Ctrl cells), and 4.414 (803-PAK6 cells) μg/ml. o–r Colony formation ability of PAK6 knocked down cells in 823 GC cell line (o, p) and PAK6 overexpression cells in 7901 (q, r) GC cell line treated with or without oxaliplatin (0.3 μg/ml in 823 cells or 0.5 μg/ml in 7901 cells). s, t Apoptosis analysis of control cells and PAK6 knocked down cells in 823 and AGS GC cells treated with or without oxaliplatin. u Apoptosis analysis of control cells and PAK6 overexpression cells in 7901 and 803 GC cells treated with or without oxaliplatin. Data presented as mean ± SD of three independent replicates. *: P < 0.05, **: P < 0.01, ***: P < 0.001, ns: no statistical difference.